Last updated: February 27, 2026
What is NDC 51672-1306?
NDC 51672-1306 corresponds to a specific pharmaceutical product. Based on available data, this code pertains to Chimeric Antigen Receptor T-cell (CAR-T) therapy, Axicabtagene Ciloleucel (Yescarta), primarily indicated for relapsed or refractory large B-cell lymphoma.
This assessment is based on standard NDC-to-product correlations and recent market activity. As the product details are critical, confirm the product label for precise validation.
Market Landscape for CAR-T Therapies
Market Size and Growth
The global oncology CAR-T cell therapy market was valued at approximately USD 1.2 billion in 2022. It is projected to grow at a Compound Annual Growth Rate (CAGR) of around 20% from 2023 to 2030.
Key drivers include:
- Increasing incidence of hematological malignancies.
- Approvals of new CAR-T products.
- Ongoing clinical trials expanding indications.
- Healthcare systems adapting to high-cost treatments with optimized reimbursement strategies.
Competitive Environment
Major products in the space:
- Yescarta (Gilead Sciences) – NDC 51672-1306.
- Kymriah (Novartis).
- Breyanzi (Janssen).
- Tecartus (Gilead).
Market share distribution (2022):
| Product |
Market Share |
Estimated Revenue (USD millions) |
| Yescarta |
50% |
600 |
| Kymriah |
30% |
360 |
| Breyanzi |
15% |
180 |
| Tecartus |
5% |
60 |
Pricing Trends and Reimbursement
Initial pricing for CAR-T therapies ranged from USD 373,000 to USD 475,000 per treatment in 2022. These figures cover therapy, manufacturing, and administration costs.
Reimbursement patterns include:
- CMS (Centers for Medicare & Medicaid Services) reimbursement models.
- Value-based agreements in private insurance.
- Hospital outpatient prospective payment system (OPPS) adjustments.
Reimbursement is shifting towards outcomes-based models, influencing effective pricing.
Price Projection for NDC 51672-1306 (Yescarta)
Current Pricing Overview
Yescarta's average wholesale price (AWP) per dose approximates USD 373,000. This encompasses:
- Manufacturing costs.
- Delivery and administration fees.
- Ancillary services.
Pricing varies by indication, patient weight, and institutional agreements.
Short-Term Projections (Next 2 Years)
- Base case: prices stabilize at USD 375,000–USD 380,000 due to manufacturing efficiencies and competitive pressure.
- Payer negotiations may reduce net reimbursement by 5–10%.
Long-Term Projections (3–5 Years)
- Entry of biosimilars or generics remains unlikely amid complex manufacturing and personalized nature.
- Slight price reduction anticipated due to increased volume and competitive pressures.
- Inflation-adjusted price could decrease to USD 350,000–USD 370,000 per treatment cycle.
External Factors Impacting Price
- Regulatory shifts toward value-based pricing.
- Expansion into earlier lines of therapy may increase volume, reducing effective therapy price.
- Innovations in manufacturing reducing costs.
Risks Potentially Affecting Price
- Manufacturing scale-up delays.
- Changes in reimbursement policies.
- Increased competition from new CAR-T therapies or alternative modalities.
Summary of Price Dynamics
| Year |
Estimated Price Range (USD) |
Key Drivers |
| 2023 |
375,000–380,000 |
Stable manufacturing, negotiations |
| 2025 |
355,000–370,000 |
Volume expansion, cost reductions |
| 2030 |
350,000–370,000 |
Market stabilization, competition |
Key Takeaways
- The product associated with NDC 51672-1306 is likely Yescarta, a leading CAR-T therapy.
- Market is growing at a 20% CAGR with stable demand in hematological cancers.
- Prices are approaching USD 375,000, with potential gradual declines to USD 350,000–370,000 over five years.
- Market drivers include approvals of expanded indications, manufacturing efficiencies, and evolving reimbursement policies.
- Competitive landscape remains robust, with Yescarta holding approximately 50% market share in this space.
FAQs
1. What are the primary indications for NDC 51672-1306?
It is primarily indicated for relapsed or refractory large B-cell lymphoma.
2. How does the price of this therapy compare globally?
Prices are higher in the U.S. (USD 373,000–USD 475,000) versus Europe and Asia, where reimbursement and negotiated discounts lower effective costs.
3. Are biosimilars likely to enter the market?
Given the complexity of CAR-T manufacturing and personalized nature, biosamilar competition remains unlikely in the near term.
4. What factors could significantly reduce this product's price?
Manufacturing innovations, increased competition, and healthcare policy shifts toward cost containment.
5. How does reimbursement influence the net price?
Reimbursement models, especially outcome-based arrangements, can substantially modify the effective price received by providers.
References
[1] Grand View Research. (2023). CAR-T Cell Therapy Market Size, Share & Trends Analysis.
[2] IQVIA. (2022). Oncology Drug Pricing and Reimbursement Trends Report.
[3] U.S. Food and Drug Administration. (2022). Yescarta (axicabtagene ciloleucel) approval details.
[4] Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for high-cost drugs.
